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Abstract 
Cardiovascular diseases are among the leading causes of increased morbidity and mortality in developed and developing countries. One 
of the most important risk factors responsible for atherosclerosis and subsequent cardiovascular diseases is hyperlipidaemia. Currently, 
hyperlipidaemias are divided into several clinical entities. The greatest risk is associated with hypercholesterolaemia. As a result, modern 
guidelines for the treatment and prevention of atherosclerosis focus predominantly on the reduction of LDL-cholesterol. Hypertrigly-
ceridaemia and atherogenic dyslipidaemia, which are responsible for a less significant increase in the cardiovascular risk, are nowadays 
secondary targets of the treatment.
During the work-up for hyperlipidaemia one of the essential actions is the exclusion of secondary causes of the lipid abnormalities. Those 
include, among others, endocrine diseases, diabetes, drugs, nephrotic syndrome, and pregnancy. Data regarding the impact of endocrine 
disease and diabetes on the lipid profile are scattered. In this review, the authors aimed to perform a thorough analysis of the available 
publications regarding the topic and the preparation of a comprehensive review dealing with the incidence, clinical features, and the 
therapy of hyperlipidaemias in patients with endocrine disease. (Endokrynol Pol 2019; 70 (6): 511–452)
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Introduction
Lipid profile abnormalities are common in patients 
visiting general practitioners and endocrinologists, 
as well as in patients admitted to hospital wards. The 
importance of this finding is connected with signifi-
cantly increased risk of atherosclerosis and its com-
plications. Current treatment guidelines focus on the 
primary and secondary prevention of cardiovascular 
events and emphasise the importance of adherence 
to lipid-lowering strategies that consist of therapeutic 
lifestyle changes and pharmacotherapy [1]. Hyperlipi-
daemia is subdivided into several clinical subclasses: 
hypercholesterolaemia, hypertriglyceridaemia, mixed 
hyperlipidaemia, and atherogenic dyslipidaemia. The 
primary target for therapy is reduction of the LDL cho-
lesterol (LDL-C) level, and the secondary aim concerns 
hypertriglyceridaemia. In referral units for treatment of 
refractory and severe hyperlipidaemias, a significant 
fraction of patients (nearly 30%) have been found to be 
suffering from secondary hyperlipidaemias [2]. There-
fore, during the clinical work-up, practitioners need to 
exclude secondary causes of lipid abnormalities. Those 
include: type 2 diabetes mellitus, alcohol abuse, and sev-
eral endocrine disorders. Endocrine-related conditions, 
excluding diabetes (e.g. hypothyroidism, glucocorticoid 
excess, sex hormones excess, etc.) might be the cause of 
up to 13% of secondary hyperlipidaemias [2]. For many 
years it has been established that several endocrine 
diseases may worsen glucose tolerance or even lead to 
overt diabetes, but the topic of secondary hyperlipidae-
mias as a result of primary endocrine disease has not 
been profoundly explored. The most common endo-
crine causes of hyperlipidaemias are hypothyroidism, 
poorly controlled diabetes, and Cushing’s syndrome. 
However, one should remember that there are also less 
common endocrine diseases that may be responsible for 
hyperlipidaemias, such as growth hormone deficiency, 
hyperparathyroidism. Hyperlipidaemia is a major risk 
factor for atherosclerosis, which in turn is responsible 
for increased cardiovascular mortality due to cardio-
vascular events (e.g. myocardial infarctions, strokes) 
[3]. Secondary hypertriglyceridaemia is connected with 
increased risk of acute pancreatitis [4]. The prevalence of 
hyperlipidaemias, certain specific features of lipid pro-
files, and additional risk of clinical problems resulting 
from untreated background endocrine disease led us to 
review the available data and provide a comprehensive 
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changes are more profound than they appear. It was 
shown that atherogenic dyslipidaemia is often develop-
ing in patients with concomitant insulin resistance, loss 
of lipoprotein lipase activity, and increased activity of 
CETP [6]. This leads to abnormalities in reverse choles-
terol transfer from arteries (low HDL-C), a change in 
LDL-C particles that become severely atherogenic, and 
an increase in TG level. All these phenomena greatly 
accelerate atherosclerosis (Fig. 1).
When diagnosing hyperlipidaemias it is essential to 
make sure that the results obtained from the laboratory 
are valid. While the certification of the majority of labo-
ratories greatly ensures clinicians that intra-laboratory 
errors should be minimised, more effort should be put 
on the pre-laboratory part, especially preparation of the 
patient for blood sampling. The patient should provide 
a fasting blood sample. The fasting status should be 
minimally 12 h, preferably 16 h. It is crucial especially 
in respect to TG, which in some patients tends to be 
elevated for prolonged periods of time due to persistent 
postprandial chylomicronaemia [7]. 
Endocrine disorders affecting lipid profile
Endocrine disorders and poorly controlled diabetes are 
responsible for nearly a quarter of cases of hyperlipi-
daemia. Therefore, during the work-up of an abnormal 
lipid profile, efforts toward exclusion of endocrine 
causes should be made. In the following paragraphs 
a description of lipid abnormalities in endocrine dis-
ease is provided. The majority of such causes may be 
diagnosed or clinically suspected based on focused 
anamnesis and physical examination. In selected cases 
detailed laboratory studies should be considered, to 
confirm the diagnosis of secondary hyperlipidaemia.
Hypothyroidism
Thyroid hormones play an important role in the metabo-
lism of lipids (Fig. 1). They increase the number of LDL 
receptors in the liver, increase synthesis of bile salts, re-
duce absorption of cholesterol from the GI tract, improve 
reverse cholesterol transfer from peripheral deposits (by 
the augmentation in ABCA1 and CETP), and increase 
the amount and activity of lipoprotein lipase and hepatic 
summary on the topic of endocrine diseases as causes 
of secondary hyperlipidaemias.
Characteristics of hyperlipidaemias
The Frederickson classification of lipid disorders is 
considered as a reference in the diagnosis of hyper-
lipidaemias. It is based on the electrophoresis and 
centrifugation of serum, and defines six types of hyper-
lipidaemias [5]. However, in everyday clinical practice, 
due to its cumbersome methodology, it is rarely used. 
Nowadays a simplified approach, based on the mea-
surement of fasting lipids [total cholesterol, triglycerides 
(TG), HDL-cholesterol (HDL-C), and LDL-cholesterol 
(LDL-C)], is routinely used. This clinical classification 
divides hyperlipidaemias into: predominant hyper-
cholesterolaemia, predominant hypertriglyceridaemia, 
mixed hyperlipidaemia, and atherogenic hyperlipi-
daemia (Tab. I) [1]. The reasoning for that is based on 
results of clinical trials showing varying levels of 
cardiovascular risk connected with elevations of lipid 
fractions. Nowadays LDL-C is considered as a major 
participant in the progression of atherosclerosis and 
its complications. Cardiovascular events are respon-
sible for a substantial proportion mortality among 
people overall. Therefore, the majority of efforts in the 
therapy of hyperlipidaemias are focused on elevated 
LDL-C. The priority of the LDL-C-lowering approach is 
changed toward hypertriglyceridaemia in patients with 
severely (> 500 mg/dL) elevated triglycerides, which is 
based on the fact that such an elevation in triglycerides 
is a strong risk factor for a potentially fatal acute dis-
ease – acute pancreatitis. But one must remember that 
when the reduction of TG has been achieved (by proper 
therapeutic lifestyle change — TLC or diet), the target 
should be switched again toward LDL-C. In mixed 
hyperlipidaemia both TG and LDL-C are elevated, 
and, unless the concomitant TGs are > 500 mg/dL, the 
LDL-C is a primary target. Atherogenic dyslipidaemia 
is a clinical entity that, at a first glance in lipid profile, 
seems like a mild mixed hyperlipidaemia. It is char-
acterised by mild elevation in TG, low level of HDL 
(< 40 mg/dL in males and < 50 mg/dL in females), 
and normal or slightly elevated LDL-C. In fact, these 
Table I. Clinically important types of abnormal lipid profile
Type of hyperlipidaemia Total cholesterol LDL-cholesterol Triglycerides HDL-cholesterol
Hypercholesterolaemia ≠ ≠ N N
Hypertriglyceridaemia N N ≠ N
Mixed hyperlipidaemia ≠ ≠ ≠ N
Atherogenic dyslipidaemia ≠/ N ≠/ N (small dense) ≠ Ø
LDL — low density lipoprotein; HDL — high density lipoprotein
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lipase [8]. Therefore, significant elevations in total and 
LDL cholesterol (reaching 30% compared to the healthy 
population) and less prominent rise in triglycerides are 
seen in patients with overt hypothyroidism. In patients 
with subclinical hypothyroidism the change in the lipid 
profile is generally not evident. The magnitude of lipid 
abnormalities correlates with TSH level. In some studies 
it was shown that even in euthyroid patients the TSH 
level correlates positively with total cholesterol, LDL-C, 
and triglycerides but negatively with HDL-C [9]. 
In patients with overt hypothyroidism, the introduc-
tion of treatment with levothyroxine has led to a reduc-
tion in total and LDL cholesterol and triglycerides. On 
the other hand, in patients with subclinical hypothy-
roidism, clinical data have shown less promising results 
[8]. Generally, in patients with TSH > 10 mIU/L the 
impact of levothyroxine on abnormal lipid profile is 
clear, which is concordant with other studies showing 
greater benefit in this group of patients with subclinical 
hypothyroidism [10].
Nowadays, it seems reasonable to perform TSH esti-
mation in all patients with hyperlipidaemia on a regular 
basis because hypothyroidism, especially subclinical, is 
a relatively common disease (1.4–11.2% of the popula-
tion) [11], may negatively affects patients’ quality of 
life, and might be a cause of increased morbidity [10]. 
What is more, the treatment of the disease is gener-
ally well tolerated, not cumbersome, and, especially 
in people with overt hypothyroidism, it improves the 
lipid profile. However, the normalisation of the lipid 
profile may not be achieved during the therapy with 
levothyroxine, which may be the result of background 
hyperlipidaemia. In such cases, a specific, lipid-lowering 
therapy should be introduced. In the majority of cases 
the drug of choice is a statin. Due to the increased risk of 
rhabdomyolysis, the initiation of lipid-lowering therapy 
with statins is not recommended until euthyreosis is 
achieved [12].
Hyperthyroidism
Hyperthyroidism is not the cause of hyperlipidaemia, 
but a very low LDL-C level, especially with signs and 
symptoms of hyperthyroidism, should urge clinicians 
to exclude subclinical or overt hyperparathyroidism. 
Figure 1. Schematic representation of metabolism of exogenous and endogenous lipids, which includes the involvement of enzymes 
and receptors that are affected in endocrine diseases. CETP — cholesterol esters transfer protein; chol — cholesterol, chylo — chylomicrones; 
chylo-r — chylomicron remnants; DM2 — type 2 diabetes mellitus; FFA — free fatty acids; GH — growth hormone; HDL — high- 
-density lipoprotein; HL — hepatic lipase; IDL — intermediate-density lipoprotein; LDL — low-density lipoprotein; LDL-R — receptor 
for LDL; LPL — lipoprotein lipase; SR-B1 — scavenger receptor B1; TG — triglycerides [69–76] 
514






Despite lipid-lowering effects of the excess of thyroid 
hormones, patients’ overall prognosis is worsened [13].
Poorly controlled diabetes
Contrary to hypothyroidism, uncontrolled diabetes 
leads to hypertriglyceridaemia and features of athero-
genic dyslipidaemia [14]. Despite statin therapy, it is 
estimated that as many as 50% of patients with diabetes 
have increased level of TG [15]. This results from mul-
tiple factors. Generally, patients with bad glycaemic 
control do not adhere to an appropriate diet, which in 
many cases contains simple carbohydrates and satu-
rated fats. Dietary fat is transported from the intestines 
in triglyceride-rich chylomicrons, responsible for a high 
level of postprandial triglycerides. In the liver, due to 
an excess of food and insulin resistance, the increased 
synthesis of TG and its excretion in VLDL is also seen. 
The TG level is further augmented by the loss of ac-
tivity in LPL due to increased production of apoCIII 
(a physiological inhibitor of LPL). What is more, due 
to alterations in lipid transfer by CETP, LDL cholesterol 
particles in those patients become very atherogenic 
— “small dense LDLs” [16]. Finally, in patients with 
significantly elevated glycaemia, an ongoing glycation 
and oxidation of lipoproteins is responsible for the ac-
celeration of atherosclerosis and its complications [17].
Hypertriglyceridaemia, especially with concurrent 
atherogenic dyslipidaemia, is a known risk factor for 
cardiovascular diseases [18]. Therefore, it should be 
treated according to standards of care. The primary goal 
of therapy is still the LDL-C level, and TG is considered 
as a second-line treatment goal. In patients with diabe-
tes the treatment of hyperlipidaemia must be multidi-
rectional. A proper therapeutic lifestyle change (TLC), 
including regular physical activity and diet, is essential. 
As a result, LDL cholesterol can be reduced by around 
10–15% after TLC [19]. Currently, it is recommended to 
reduce LDL-C in patients with type 2 diabetes below 
70 mg/dL. Therefore, in many cases cholesterol-lower-
ing therapy should be introduced at the initial visit. TG 
level below 500 mg/dL may be initially dealt with by 
a three-month watch-and-wait strategy for the effects 
of TLC (± statin). Due to a proper diet, physical activity, 
and in some cases statin use, remarkable improvements 
in lipid profile are seen [20]. Conversely, the treatment 
with fibrates and/or omega-3 fatty acids should be im-
mediately introduced in severe hypertriglyceridaemia 
(> 500 mg/dL) or the lack of benefit after TLC or statins.
Cushing’s disease
Compared to hypothyroidism and diabetes, secondary 
hyperlipidaemia due to elevated, autonomous secre-
tion of glucocorticoids is much less common. On the 
other hand, 52% of patients with hypercortisolism are 
affected by secondary lipid abnormalities [21]. It may 
be seen more often as the result of the treatment with 
glucocorticoids (as immunosuppressive agents or exces-
sive substitution). The risk of developing cardiovas-
cular complications is increased even in subjects with 
“non-functional” adrenal tumours. It was shown that 
the higher the level of cortisol in 1 mg dexamethasone 
suppression test (all results within < 1.8 ug/dL), the 
higher the likelihood of developing diabetes [adjusted 
RR = 1.87 (1.17, 2.98)] [22]. The cardiovascular risk is 
additionally elevated in the group with subclinical 
hypercortisolism [23]. In respect to the lipid profile, 
glucocorticoids tend to cause atherogenic dyslipidaemia 
(high TG and low LDL-C), which is commonly connect-
ed with central obesity and metabolic syndrome [24].
Naturally, the treatment of choice is the elimina-
tion of hypercortisolism. This can be best achieved by 
the surgical resection of adrenal or pituitary adenoma 
(especially in overt hypercortisolism) or fine-tuning the 
cortisol replacement therapy. As a result, a significant 
improvement, but generally not normalisation, in the 
lipid profile, described by reductions in TG and LDL-C 
and an increase in HDL-C, can be achieved [21]. When 
curative treatment is not possible, a general approach 
to treat hypercortisolism, including ketoconazole or 
mitotane, is introduced. Additionally, significant effort 
should be focused on the reduction of cardiovascular 
risk factors. Therefore, a therapeutic lifestyle change is 
advised. In the majority of cases, the treatment of ath-
erogenic dyslipidaemia must include pharmacotherapy. 
All standard groups of drugs can be used, depending 
on the mostly elevated lipoprotein fraction (statins in 
predominant hypercholesterolaemia and fibrates in 
predominant hypertriglyceridaemia). It should be kept 
in mind that in patients treated with ketoconazole, 
which is a potent cytochrome P450 inhibitor, clinically 
significant drug interactions with lipid-lowering drugs 
may occur. In the necessity of combined therapy with 
ketoconazole and statins, pravastatin should be used as 
the drug of choice. Additionally, in cases of suspected 
Cushing’s syndrome in patients on lipid-lowering ther-
apy, one should consider cessation of fibrate, because 
in specific circumstances it can lead to false positive 
diagnosis of hypercortisolism. Fenofibrate interferes 
with the assay of free cortisol from urine specimens. If 
the drug cannot be withdrawn, other confirmatory tests 
for hypercortisolism should be selected [25].
Pituitary diseases
Hyperprolactinaemia
Hyperprolactinaemia affects various aspects of lipid 
and glucose metabolism and leads to atherogenic dys-
lipidaemia, primarily with elevated triglycerides and 
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LDL-C [26]. The influence on the lipid profile results 
mainly from the inhibitory effect of prolactin on LPL 
[27]. Additionally, with the increase in the diameter of 
adenoma subsequent failure of the pituitary gland oc-
curs, leading to GH deficiency, hypogonadism, and, in 
severely advanced disease, to hypothyroidism, which 
are responsible for augmentation of lipid abnormali-
ties. Interestingly, it was noted that in female patients 
with macroprolactinaemia the HDL-C level is decreased 
by around 11% compared to healthy women [28]. 
The therapy of hyperprolactinaemia with dopamine 
agonists is effective also in the improvement of lipid 
profile. Total cholesterol and LDL-cholesterol have been 
significantly reduced following such a therapy [29]. In 
patients with increased level of TG, further improve-
ments may be achieved by the addition of fenofibrate 
to the therapy [30].
Acromegaly
Different kinds of lipid abnormalities are diagnosed 
in 33% of patients with acromegaly [31]. According to 
data from small-sample observatory studies, 19-56% 
of patients with acromegaly had increased level of 
triglycerides, which is significantly more than among 
age-matched individuals [32, 33]. Conversely, the cho-
lesterol level is generally mildly elevated in the course 
of the disease [34]. It seems that the elevated TG level is 
connected with increased synthesis of fatty acids and re-
duced activity of LPL [35]. This results in the elevation of 
triglyceride level, which may trigger acute pancreatitis, 
which is occasionally seen in such patients. Additional 
risk factors that may aggravate hyperlipidaemia are 
hormonal insufficiencies of other pituitary endocrine 
axes (e.g. secondary hypothyroidism, hypogonadism), 
which are caused by compression trauma in macroad-
enomas. Lipid abnormalities in patients with acro-
megaly were shown to be responsible for accelerated 
progression of subclinical atherosclerosis (intima media 
thickness and pulse-wave velocity), which in turn may 
be responsible for increased cardiovascular risk [36]. It 
was also noted that the risk of cardiovascular complica-
tion is considerably elevated and correlates positively 
with the duration of acromegaly [37].
The greatest improvements in lipid profile are ob-
served in patients after successful surgical treatment 
of adenoma. Subsequently, the lipid profile improves 
significantly, which is reflected by a drop in TG con-
centration. In a paper showing a series of cases of 
surgically treated patients, the reduction in TG level 
reached 50.7% (p = 0.004) [38]. The improvement dur-
ing the treatment of acromegaly is strictly related to the 
achieved reduction in GH, which leads to increased 
activity of LPL and finally to the reduction of TG [39, 
40]. Recent clinical trials have shown that the lipid 
profile improvements are the result of the achievement 
of control of the disease. Somatostatin analogues have 
led to significant reductions in TG level, which was ac-
companied by a rise in HDL-C [41]. Lipid abnormalities 
that are concurrent with acromegaly should be treated 
according to general guidelines in the treatment of 
hyperlipidaemias. Therefore, after cardiovascular risk 
estimation, treatment with statins or fibrate should 
be introduced. In the case of patients on somatostatin 
analogues, prior to the introduction of fibrate, gallstones 
should be excluded. Fibrates are contraindicated in 
those patients due to increased cholesterol content in 
bile, which is responsible for increased propensity for 
gallstone formation [42].
Growth hormone deficiency
In children, growth hormone deficiency leads to growth 
retardation. The majority of patients are withdrawn 
from the GH substitution on entering adulthood or 
when satisfactory height is achieved. Interestingly, 
adult patients with GH deficiency in many countries 
have been on hormone replacement therapy to pre-
vent metabolic complication for the last 30 years [43]. 
The incidence of metabolic syndrome in adult patients 
with GH deficiency is more than doubled compared 
to healthy subjects (38.0 vs. 15.7%, p < 0.0001) [44]. 
Detailed analysis of the lipid profiles of those patients 
revealed significantly elevated LDL-C and TG (in 85% 
and 44% of patients, respectively), which were often 
accompanied by a reduction in HDL-C (in 47% of pa-
tients) [45]. Such a lipid profile should be considered 
as atherogenic dyslipidaemia. 
GH replacement therapy in children has shown 
improvements in lipid profile, which may prevent 
atherogenic complications in the future [46]. How-
ever, the improvements in lipid profile in adults are 
less evident, showing persistent atherogenic dyslipi-
daemia during up to five years of the treatment or 
only minor (5%) reduction in total cholesterol [47]. 
Interestingly, in patients following effective treatment 
for acromegaly, who developed GH deficiency, GH 
replacement therapy seemed to improve lipid profile 
[48]. In conclusion, the impact of GH itself on lipid 
profile and long-term benefits in adults are less clear 
[49]. Therefore, it seems that the active treatment of 
dyslipidaemia with hypolipidemic drugs should be 
introduced according to the estimated cardiovascular 
risk or concomitant diseases to prevent further ath-
erosclerotic complications.
Combined pituitary hormone deficiency 
Combined pituitary hormone deficiency (CPHD) is di-
agnosed when there is a deficiency or absence of at least 
two pituitary hormones. The genetic background relies 
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on mutations of several proteins associated with the de-
velopment of pituitary gland and subsequent secretion 
of hormones (e.g. Pit-1, PROP-1). Clinical manifestations 
may vary, depending on major hormone deficiencies, 
but a rise in total cholesterol and LDL-C is commonly 
seen [50]. The most probable cause of hypercholester-
olaemia in those cases is secondary hypothyroidism. 
Therefore, successful treatment of hypothyroidism 
generally leads to the normalisation of cholesterol level. 
Naturally, in those specific and rare cases, prior to the 
administration of levothyroxine, a secondary adrenal 
gland insufficiency must be excluded.
On the other hand, in patients suffering from Shee-
han’s syndrome, various hyperlipidaemias have been 
diagnosed, which were connected with the reduced 
level of lipoprotein lipase and hepatic lipase activity 
[51]. Reduced activity of both lipases is responsible for 
various forms of hyperlipidaemias with predominant 
hypertriglyceridaemia. The introduction of proper 
hormonal substitution with hydrocortisone and levo-
thyroxine resulted in the reconstitution of lipase activity 
and normalisation of lipid profile.
Polycystic ovary syndrome 
Polycystic ovary syndrome (PCOS) may affect up 
to 20% of the population of otherwise healthy fe-
males. The majority of clinical problems that lead to 
seeking for help result from infertility and patients 
changed body appearance due to hyperandroge-
naemia. However, due to androgen excess those 
patients suffer from atherogenic dyslipidaemia [52]. 
The greatest benefits can be achieved by therapeutic 
lifestyle change leading to reduced body weight and 
increased physical activity. Some lipid benefits (reduc-
tion in LDL-C and TG) are seen after the introduction 
of metformin [53]. In the older population or in those 
with additional cardiovascular risk factors, targeted 
treatment of lipid abnormalities can be offered. Nev-
ertheless, it should be noted that statin therapy may 
worsen glucose sensitivity in this specific vulnerable 
population [54]. 
Oestrogen/progesterone excess and oral 
contraception
Combined oral contraception (COC) and progestin-on-
ly oral contraception (POC) are methods of contracep-
tion used by around 13% of women [55]. Combined oral 
contraception has been shown to increase triglyceride 
and total cholesterol (mainly by an increase in HDL-C), 
whereas POC seemed to have neutral impact on lipid 
profile. COCs are contraindicated in severe dyslipidae-
mia, especially in patients with elevated TG, due to the 
increased risk of acute pancreatitis. In this clinical set-
ting intrauterine devices should be recommended [56].
Hypogonadism
Male hypogonadism may arise from testicular dam-
age (primary hypogonadism) or as a consequence of 
hypothalamic-pituitary axis insufficiency (secondary 
hypogonadism). The diagnosis is generally made by 
the presence of clinical signs and symptoms with con-
current low level of testosterone taken on several occa-
sions [57]. Nowadays, a substantial group of patients, 
due to obesity, develop secondary hypogonadism 
[58]. Obesity and metabolic syndrome lead to a mild 
atherogenic dyslipidaemia. Testosterone replacement 
therapy improves patients’ quality of life and glucose 
metabolism, but its impact on the lipid profile is less 
apparent. Reductions in total cholesterol and TG are 
minute (generally < 5%) [59, 60]. During the therapy, 
improvements in markers of cardiovascular diseases 
(e.g. apoB) have been noted [61], but the impact on 
cardiovascular outcomes remains inconclusive due to 
the lack of data of sufficient quality [62].
In postmenopausal women, a tendency toward 
increased levels of total cholesterol and LDL-C triglyc-
erides, and reduced level of HDL-C has been noted 
[63]. The LDL-C level is increased in more than 48% of 
patients, low HDL-C level is seen in more than 42% of 
patients, and high TG in nearly 30% of patients. Lipid 
profile abnormalities and additional metabolic changes 
(obesity, arterial hypertension, and insulin resistance) 
lead to increased risk of cardiovascular events [64]. 
Despite the change in lipid profile that is attributed 
to ovarian failure, hormone replacement therapy 
with oestrogen and progesterone has not reduced the 
cardiovascular risk and markers of subclinical athero-
sclerosis in postmenopausal women [65]; nowadays it 
is not recommended in cardiovascular prevention but 
merely for symptomatic relief. Therefore, in postmeno-
pausal women with abnormal lipid profile a targeted 
hypolipidemic therapy (e.g. statin, fibrate) should be 
introduced.
Hyperparathyroidism
In patients with primary and secondary hyperparathy-
roidism, a predominant increase in TG level has been 
noted. More than 52% of patients suffer from some sort 
of hyperlipidaemia [66], which is 50% higher than the 
incidence of hyperlipidaemia in the population from 
the same background. The reason for that is not fully 
understood, but patients with hyperparathyroidism 
more often suffer from obesity and diabetes, which may 
be related to reduced physical activity. However, it has 
also been shown that the TG level rapidly dropped in 
patients with primary hyperparathyroidism as soon 
as seven days after surgery of parathyroid adenoma 
(1.50 ± 0.11 to 1.19 ± 0.07 mmol/L; p < 0.001) and has 
been maintained at a lower level for up to 12 months 
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of follow-up (1.17 ± 0.11 mmol/L) [67]. On the other 
hand, other researchers have shown that parathyroid-
ectomy did not lead to any significant change in lipid 
profile [68]. The differences in favour of non-surgically 
treated patients have been attributed to lipid-lowering 
therapy. Therefore, the curative method in the treat-
ment of hyperthyroidism is a surgical approach, but it is 
indicated in patients with clinical or laboratory features 
that support such treatment. On the other hand, in pa-
tients who are not treated operatively, a mild increase 
in TG or LDL-C level can be successfully treated with 
lipid-lowering drugs. 
Conclusions
Endocrine disorders are relatively common causes of 
secondary hyperlipidaemia. The wide variety of lipid 
profile abnormalities makes it nearly impossible to spe-
cifically suspect endocrine disease (Tab. II). However, 
due to the fact that the thyroid function abnormalities 
and hypercholesterolaemia are often seen in the general 
population, it is recommended to exclude hypothy-
roidism in every patient with hypercholesterolaemia 
(generally, TSH measurement is sufficient). Due to 
strict recommendations regarding LDL-C levels, the 
lipid profile in patients with type 2 diabetes is generally 
regularly checked concomitantly to markers of glucose 
control (HbA1c). Therefore, worsening of lipid profile 
may swiftly be correlated with glucose levels and proper 
diet or using pharmacological therapy. In the majority 
of hyperlipidaemias, the suspicion of endocrine disease 
should be based on a clinical approach rather than on 
simple lipid profile estimation (e.g. red stretch marks in 
Cushing’s disease or reduced sexual drive in hypogo-
nadism). The treatment of secondary hyperlipidaemias 
in many cases is focused on the offending endocrine 
disease, but in the majority of cases it must be strength-
ened by specific lipid lowering therapy. 
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